Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (20495)	5/11/1998 7:09:00 PM
From: bob zagorin	Respond to of 32384

BOP fell back a bit today, just below green into the yellow (which still shows positve accumulation). With major news, BOP should take a back seat tomorrow.

To: Andreas Helke who wrote (20495)	5/11/1998 7:59:00 PM
From: Torben Noerup Nielsen	Read Replies (2) \| Respond to of 32384

Andreas, >I am still astonished that a treatment of a rare disease like CTCL >makes a significant difference to the earnings of a medium sized >biotech company I believe I saw numbers of about 16,000 new cases per year. Also, I saw numbers of $5,000 - $60,000 per year for current treatment. Assume that those numbers are correct (or correct me if you have better ones) and that LGND with this takes 5,000 new patients per year (combination treatment) and charges $10,000 per patient (not so unreasonable). That would make $50,000,000 in revenue per year unless my arithmetic is flawed. What you need to keep in mind is that cancer treatment is expensive and that even small patient populations can give you pretty big revenues. There is also the potential for much higher revenues if they take a larger share of the patient population. Cheers, Torben